Category Archives: Cell Biology

Biological Microscope Objectives Market Current Trends, Business Strategies and Industry Overview 2020 to 2025 – Bulletin Line

Meridian Market Consultants (MMC) has published a new report titled, 2020-2025 Global and Regional Biological Microscope Objectives Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report (Enhanced Version).According to the report,Global Biological Microscope Objectives Market, is expected to grow at a significant CAGR for the period between 2020 and 2025.

Get Exclusive Sample Copy of the Report@ https://meridianmarketconsultants.com/requst?rid=%20111230647

As per the report,the microscopes are plugging away in numerous fields with its potential to enlarge and glorify the representation of an object that cannot be observed through bare eyes, thereby the global biological microscope objective market is witnessing a satisfactory growth these days. Fundamentally, a kind of microscope which promotes its utility in order to examine tissues, cells, and other biological specimens, is known as a biological microscope.

Furthermore, one of the most important constituents of an optical microscope is a microscope objective as it forms the primary image and is solely responsible for the quality of the image that the microscope is going to produce. In addition to that, the microscope objective is helpful in enlarging or glorifying a specific biological sample so that each and every fine detail of the sample can be observed.

Notably, the name of the microscope objectives is derived from the fact that they are the only component that is closest to the specimen that is being imaged. As a matter of fact, the researchers are always in constant requirement for new and advanced objective lenses to examine unique kinds of substances, cells and other objects as closely as possible. Owing to which, the technological advancements intended at bringing novelty in objective lenses have been very common in the present times. Attributing to such factors, the global biological microscope objectives market is expected to flourish positively in the near future.

Ask for [emailprotected]https://meridianmarketconsultants.com/ask-for-customization?rid=%20111230647

In the similar manner, the comprehensive demand of the biological microscopes is also projected to quicken the growth of the global biological microscope objectives market in the forthcoming future as it serves its application in semiconductor, material science, pharmaceutical, life science, and biotechnology industries.

More essentially, the microscope objectives assist in blood microscopy, cell biology research, immunohistochemistry in cancer research, sputum microscopy, urine analysis, and many more, thus the field of life sciences observe high demand of biological microscopes, in turn supporting the growth of the global biological microscope objectives market.

Along with that, several key market players are aiming their attention at product integration with the automated platforms in order to grow their applications in the field of material as well as life sciences.

Remarkably, the wide usage of microscope objectives potentially boosts its operational efficiency in different applications including manufacturing units and hospitals. Hence, the global biological microscope objectives market is projected to augment rapidly in the coming years.

Ask Industry Expert @https://meridianmarketconsultants.com/ask-analyst?rid=%20111230647

MMC study identifies some of the key participating players in the biological microscope objectives market globally are ZEISS International, Olympus Corporation, Nikon Instruments Inc., Leica Microsystems, Meiji Techno, and Newport Corporation, among several others.

About Meridian Market Consultants:

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as a creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the clients needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

1321, Louetta Road,

#440, Cypress, Texas, 77429

United States

Tel: +1-(281)-619-8646

For Sales Query:[emailprotected]

Find Us on Linkedin: https://www.linkedin.com/company/meridian-market-consultants

Here is the original post:
Biological Microscope Objectives Market Current Trends, Business Strategies and Industry Overview 2020 to 2025 - Bulletin Line

The Drug Supply Chain Is Broken. A New Breakthrough Paves The Way For On-Demand Plant-Based Medicines – Forbes

When Covid hit and hospitals started reporting drug shortages, it became clear that our drug supply ... [+] chain was broken. In a Nature paper, Christina Smolke reports a breakthrough in making plant-based medicines that lays the foundation for a flexible, on-demand drug supply chain. Photo by The Tonik on Unsplash

When Covid hit and hospitals started reporting shortages of hydroxychloroquine and other medicines vital to patients with conditions like malaria, lupus, asthma, and COPD, it became clear that our drug supply chain was broken.

Nearly all plant-based medicines including hydroxychloroquine are made outside the US because the medicinal plants used to make them grow in very particular climates. For example, India manufactures 70% of the world's supply of hydroxychloroquine. (India initially banned the drugs export to the US but later reversed its decision after President Trump threatened retaliation.)

Plant-based drugs have long been subjected to production limitations and medical shortages. Environmental disasters like the Australian wildfires or sudden spikes in the demand (similar to what the US experienced at the onset of the pandemic) can result in patients lacking desperately needed medicines.

Were experiencing a number of challenges with supply chains for pharmaceuticals today, especially in supply chains that are based upon farming, says Stanford professor Christina Smolke.

In a Nature paper published today, Smolke and her lab report a breakthrough in making plant-based medicines that lays the foundation for a flexible, on-demand drug supply chain to replace our current fragmented and slow-moving one. The solution: use yeast instead of plants.

Using the tools of synthetic biology, which combines advances in our ability to edit DNA with computation and automation, Smolkes lab successfully added the genes from plants into bakers yeast that make drugs called tropane alkaloids. This class of drugs includes hyoscyamine and scopolamine, two traditional drugs used to treat neuromuscular disorders like Parkinson's as well as nausea from motion sickness and surgery.

Stanford professor Christina Smolke

Smolkes lab had previously demonstrated a similar ability to engineer yeast to ferment opioids, another plant-based class of medicines. That process added over twenty genes from five different organisms to yeast cells, resulting in the first narcotic produced using synthetic biology. But the project reported today was far more challenging and has bigger implications for the way we make plant-based medicines.

The way that plants have evolved to make tropane alkaloids is through a very complicated biosynthesis scheme, says Smolke. In nature, the pathway depends on enzymes that only work in specific tissues, cell types, and organelles within the plant.

Smolkes team took what it calls a whole-cell engineering approach to the problem. It not only rebuilt the pathways 26 different enzymes and proteins in yeast, but it also recreated the cellular microfactories needed for the pathway to work as it would in plants. This included special transporter enzymes that shuttle the intermediate chemical into and out of the various microfactories as needed during biosynthesis of the chemical. Replicating these various cellular processes in a single microorganism like yeast has never been done.

The result: the same basic yeast that makes bread and wine can now also ferment some of the most complex molecules known to humankind.

The research is a strong indicator that the vast majority of plant-based drugs can be produced through industrial fermentation in the coming years. Rather than the months or years it takes to grow, harvest, and extract key molecules from medicinal plants, a fermentation-based manufacturing approach can be implemented in any location and takes just days to produce target compounds, enabling the production of essential medicines when and where theyre needed.

Smolkes research also sets the stage for others to discover improved drugs starting from the original. By making thousands of individual changes to the original biosynthetic pathway, scientists can discover new tropane alkaloid derivatives with new properties, which could be useful as new therapeutics for CNS disorders.

This type of work lays the foundation for being able to develop a bio-based fermentation process for producing these and related molecules, says Smolke.

In 2013, Smolke founded Antheia, a biotech startup that is bringing to market next-generation plant-inspired medicines like these. Antheia developed a fermentation process that takes the work from the lab to commercial scales. These days, Smolke spends most of her time at Antheia, turning her labs research into commercial products.

I think it's a very unique opportunity as an engineer to have a hand in both innovating the breakthrough research that underlies these innovations and then guiding them to commercialization, Smolke says. There's a lot of steps beyond what we would do in an academic lab to actually bring something to the stage where it can have a real impact in the world.

Follow me on Twitter at @johncumbers and @synbiobeta. Subscribe to my weekly newsletters in synthetic biology. Thank you to Kevin Costa for additional research and reporting in this article. Im the founder of SynBioBeta, and some of the companies that I write about are sponsors of the SynBioBeta conference and weekly digest. Heres the full list of SynBioBeta sponsors.

See the original post here:
The Drug Supply Chain Is Broken. A New Breakthrough Paves The Way For On-Demand Plant-Based Medicines - Forbes

ASCB receives grant to develop tools for curation of scientific literature – Newswise

Newswise The American Society for Cell Biology (ASCB) will experiment with innovative approaches to categorize the scientific significance of reported research without dependence on journal name brands. The Society was one of three organizations selected by the Wellcome Trust and the Howard Hughes Medical Institute to receive the first Learned Society Curation Awards, which are designed for organizations that want to explore new ways of signaling the significance of published research outputs in an open and transparent manner.

The advent of preprints, the rapid expansion of journals and peer-reviewed publications, and the movement away from journal names as a proxy for impact are challenging the ability of authors, readers, and evaluators to assess the impact of scholarly works. The projects outlined in the grant proposal are designed to leverage the expertise of the ASCB community to help address this problem, wrote Molecular Biology of the Cell (MBoC) Editor-in-Chief Matthew Welch in the grant application.

Badges and significance statements will be attached to selected MBoC articles, but an important goal of the project will be to also apply these tools to preprints. Welch will assemble an editorial board of early-career scientists who will curate preprints by assessing their contributions to the field and applying the appropriate badges and significance statements.

We are excited to implement these innovations to help readers appreciate the impact of work published in MBoC and posted on preprint servers, Welch said. Its particularly exciting to involve and engage a new group of early-career editors in these editorial and curatorial experiments.

The goal of the new editorial board will be to quickly grasp the importance of a published work, to label the articles contributions in a number of categories, and to provide readers with concise statements of a works significance. Digital badges will highlight research contributions such as presenting a new concept, a technical advance, or a translational advance; being broadly relevant, or serving as a teaching resource.

As digital objects, the badges and significance statements will not be embedded in an article but can be attached to the article wherever it is mentioned, such as on its abstract or in a table of contents. ASCB will be collaborating with Cold Spring Harbor Laboratory, operator of the preprint server bioRxiv, to create a means to place the objects on preprints.

ASCB will hire a half-time Curation Manager to help run this program. The job description can be found at http://www.ascb.org/about-ascb/work-with-the-ascb and will be open until a suitable candidate is hired.

See original here:
ASCB receives grant to develop tools for curation of scientific literature - Newswise

Dr. Fauci will be a guest speaker on a free online MIT class about the science of the pandemic – Time Out

Starting today through December 8, 2020, folks around the country will be able to partake in a free online class led by MIT professors Richard Young and Facundo Batista focusing on the science of the pandemic. Dr. Anthony Fauci is listed among the special guest speakers.

You won't have to register for the course but will simply be able to live stream the weekly affair every Tuesday at 11:30am EST by clicking on this link. To access the video, use password mit-covid. A note: although the lecture will be accessible by all, only registered students will be allowed to ask questions during the Q&A portion of the class.

Check out the syllabus in its entirety right here.

According to the official description of the course, attendees can expect to learn more about the fundamentals of COVID-19, plus lessons on clinical disease, vaccine and therapeutic development, immunology, cell biology and more.

Dr. Fauci is scheduled to appear on camera onSeptember 22 to deliver "insights from the COVID-19 pandemic." Other guest speakers include Harvard's Michael Mina, who will discuss all things epidemiology on October 27, Yale's Akiko Iwasaki, who will dive into immunology and antibodies on November 17, and the Broad Institute's Eric Lander, set to discuss rapid research response in a pandemic on December 8.

Remember: information is power and there's nothing like the present. This is the perfect time to learn a bit more about a virus that has literally taken us all by storm and upended lifestyles all across the globe. The best part?The course is completely free.

Most popular on Time Out

-Funny things to ask Siri that will provoke uncontrollable laughter-Online trivia games to play remotely-Online party games to play remotely with friends-The creepiest ghost towns in America you can actually visit-This map highlights what Americans in each state like to snack on while studying

Excerpt from:
Dr. Fauci will be a guest speaker on a free online MIT class about the science of the pandemic - Time Out

CAR T-Cell Optimization Starts in Production, Extends to Therapy – Genetic Engineering & Biotechnology News

Just as heat-seeking missiles race toward the infrared signatures of their targets, chimeric antigen receptor (CAR) T cells home in on cancer-associated or -specific antigens. Once the antigens are engaged, CAR T cells let fly with cytotoxic flak, granules containing perforin and granzymes, while activating supplementary tumor-killing mechanisms such as stromal sensitization and macrophage polarization. It is to be hoped that by the time the cytotoxic smoke clears, the cancer will have been destroyed.

The development of CAR T cells has revolutionized adoptive cellular therapies against cancer. CARs are genetically engineered to combine antigen- or tumor-specific-binding with T-cell activating domains. T cells, obtained from the patient (autologous cells) or from a healthy donor (allogeneic cells), are typically transduced with an engineered vector, expanded, and infused back into the patient for tumor eradication.

In the 10 years since its inception, the CAR T-cell field has progressed rapidly. Two CAR T-cell products have been approved for clinical use, and many more products are undergoing clinical trials or are in development. Although the field initially focused on B-cell malignancies, it is now advancing on solid tumors.

Despite its initial success, the CAR T-cell field must find ways to generate products that are potent, affordable, and available. To achieve enduring success, the CAR T-cell field is undertaking a range of initiatives. These include the engineering of bridging proteins for multiantigen targeting; the creation of nonviral allogeneic off-the-shelf products; the organization of vein-to-vein networks; and the development of precisely tuned therapies, that is, precisely timed and dosed therapies.

Cellular therapy is a living drug, declares Steve Shamah, PhD, senior vice president, Obsidian Therapeutics. As with any drug, damage can occur if the therapy is not carefully regulated. Our company focuses on creating controllable cell therapies by engineering CAR T cells or tumor-infiltrating lymphocytes to produce regulatable cytokines and proteins that can enhance functional activity, especially against solid tumors.

For example, the company is developing a platform that armors CAR T cells with immunomodulatory factors such as interleukin-15 (IL-15) or CD40 ligand. Shamah explains, These factors can enhance functional activity by driving T-cell expansion, conferring resistance to immunosuppression, improving antigen presentation, and inducing antigen spread. However, both factors can also produce systemic toxicity. Our technology modulates the level and timing of their activity in a fully controlled, dose-dependent manner using an FDA-approved small-molecule drug.

The Obsidian platform, cytoDRiVE, adds a drug-responsive domain (DRD) onto a therapeutic protein of interest. DRD tags are misfolded or inherently unstable in the cell. However, they can be reversibly stabilized by the binding of approved small-molecule drugs. When the drug is absent, the DRD-tagged protein is turned off. When the drug is present, the DRD-tagged protein is turned on. When DRD tags are in place, the concentration of the small-molecule drug serves as a biological rheostat for controlling the dosing of the therapeutic protein.

Preclinical in vivo mouse studies assessed anti-CD19 CAR T cells that were engineered to express an IL-15-DRD that responded to the FDA-approved drug acetazolamide. In these studies, tumor regression was demonstrated.

Controlling the precise timing and expression level of these immunomodulatory factors in CAR T cells could significantly enhance safety and therapeutic efficacy, concludes Shamah.

Obsidian is currently focusing on the oncology space, but the company is also exploring other areas such as autoimmunity and even the regulation of transcription factors to enable controllable in vivoCRISPR-Cas9 gene editing.

Despite the remarkable success of CAR T-cell therapies, relapses can occur within six months for up to 50% of patients treated with anti-CD19 CAR T-cell therapy.Failures can occur due to loss of CD19 expression or to continued tumor proliferation. Aleta Biotherapeutics has developed a novel technology to reactivate CAR T cells in relapsed patients.

Our approach utilizes antigen-bridging proteins to coat tumors with CD19, says Paul Rennert, PhD, Aletas president and CSO. [The tumors are then] recognized by the patients anti-CD19 CAR T cells, essentially creating a cytotoxic synapse that results in tumor cell death.

To thwart anti-CD19 CAR T-cell therapy relapses, the company developed a bridging protein using the extracellular domain of CD19 and an anti-CD20 antibody domain. CD20 is an antigen present on the majority of B-cell malignancies. Rennert explains that these injected bridging proteins will coat the patients tumor cells with CD19, creating a target to activate or reactivate a patients anti-CD19 CAR T cells.

To show proof-of-principle, the company performed in vivo studies using a half-life-extended form of the bridging protein injected into mice carrying CD20-positive tumor cells and anti-CD19 CAR T cells. Rennert emphasizes, Our studies demonstrated this strategy can be used to reactivate CD19 CAR T cells to prevent and reverse relapses.

Other programs in development include a bridging protein for injection to improve outcomes in multiple myeloma patients treated with CAR T cells, and bridging protein programs for HER2-positive breast cancer patients with central nervous system metastases. The company is preparing investigational new drug applications for its technology and plans to start Phase I trials in 2021.

Assessing whether engineered CAR T-cell and T-cell receptor (TCR) therapies have successfully attacked and penetrated solid tumors (and not normal cells) can be like finding the proverbial needle in the haystack. Traditional methods using immunohistochemistry are useful for immune profiling, but they cannot differentiate engineered versus endogenous cells, points out Christopher Bunker, PhD, senior director of business development, Advanced Cell Diagnostics, a Bio-Techne brand. We developed a means to easily detect and track engineered therapeutic cells and delineate their pharmacokinetics within the tumor microenvironment of intact tumor biopsies, as well as their on-target/off-tumor activity.

Enter RNAscope, an RNA in situ hybridization technology that can enable single-cell spatial transcriptomics. RNAscope, Bunker asserts, is the only off-the-shelf method that can specifically detect engineered CAR T cells and TCR T cells in solid tumor patient biopsies.

Most cell therapies employ lentivirus transduction. Because CAR or TCR transgenes have unique sequences in the viral untranslated regions, these can be used as tags for identification of engineered cell therapies with RNAscope probes. The technology utilizes pools of paired oligos that can be thought of as a ZZ pair, where the paired 3 ends hybridize to ~50 bases of target mRNA, and where the paired 5 ends hybridize to a signal amplification module, which is built through sequential hybridization steps. The signal amplification of paired oligos results in an assay able to detect individual transcripts that appear as visible and quantifiable dots.

Its a little like planting and lighting Christmas trees, quips Bunker. The ZZ pairs plant trees along the mRNA with branches that are decorated either with fluorophores or chromogens. Although the primary technology currently features four colors, the company has developed a HiPlex (12-plex) assay and foresees even higher-plex assays with different detection methods.

We envision assays based on our core technologies that enable spatial analysis of perhaps a hundred transcripts in combination with tens of proteins, Bunker projects. In the context of cell therapy development, these will enable a more comprehensive understanding of tumor biology and immune cell profiles to determine the most effective treatment strategy for a patient, as well as for monitoring efficacy of solid tumor cellular therapies.

Companies developing CAR T-cell products are also eyeing a future involving GMP production. Thus, a critical early question is how to choose the best T-cell medium for manufacturing processes. To test the suitability of a CAR T-cell growing medium, companies must assess factors such as cell viability, cell expansion, cytokine profiles, and cell purity. A medium suitable for a CAR T-cell manufacturing process also needs to support rapid activation and CAR transduction. Additionally, the selected medium needs to be compatible with a variety of donors.

There are many available choices for T-cell culture media ranging from do-it-yourself recipes to commercially available one-size-fits-all complete formulations. CellGenix has developed a novel T-cell medium that avoids the use of human serum. Sebastian Warth, PhD, a senior scientist at CellGenix, explains, To achieve consistent results, human serum requires extensive testing prior to its use for production of cellular products due to lot-to-lot inconsistencies. Since human serum is a limited resource and might not be available in large quantities, it is unfavorable for commercial-scale manufacturing. Furthermore, the human origin of serum poses a certain risk of containing adventitious agents and is, therefore, a risk to the safety of the T-cell therapy product.

The companys TCM GMP-Prototype medium provides a serum-free and xeno-free product for early-onset T-cell expansion. According to Warth, key advantages include promotion of sustained viability, support for expansion of CD4+ and CD8+ T cells, promotion of a central memory and early differentiated memory T-cell phenotype, and maintenance of a high proportion of cytokine-producing cells including polyfunctional cells. Further, it was optimized for and verified with CAR T cells.

While autologous CAR T-cell therapies have proven highly successful, they also require a long and expensive manufacturing process. The dream of being able to utilize off-the-shelf allogeneic T cells is on the horizon.

Devon J. Shedlock, PhD, senior vice president, research and development,Poseida Therapeutics, reports, With our technology, we are able to genetically modify cells to create a fully allogenic, or off-the-shelf, product that does not require additional immunosuppression treatment like earlier generation approaches. We also have developed technology to allow us to make hundreds of doses from a single manufacturing run from healthy donors, thereby dropping the cost substantially.

According to Shedlock, the technology consists of three key aspects: 1) the piggyback DNA Modification System, 2) the Cas-CLOVER site-specific gene editing system, and 3) the Booster Molecule.

The PiggyBac DNA Modification System is a nonviral technology for stably integrating genes into DNA. One key feature is that piggyBac preferentially inserts into less mature T cells, enabling the production of therapies that have a high proportion of stem cell memory T cells, or Tscm cells.

Viral technologies are virtually excluded from Tscm cells, Shedlock states. However, Tscm cells are the ideal cell type for cell-based therapies because they have the ability to engraft and potentially last a lifetime, can produce wave after wave of more differentiated cells to attack the tumor, and are much more tolerable with low levels of adverse events compared to other CAR T-cell products.

The companys Cas-CLOVER gene editing technology is a hybrid gene editing technology used to edit the T cells to make allogeneic products. Cas-CLOVER works well in resting T cells, which is important in preserving Tscm cells in a fully allogeneic CAR T-cell product, Shedlock elaborates. It also is a very precise and clean system. This is a particularly important safety issue for allogeneic products that may be given to many patients.

The Booster Molecule is added during manufacture and is temporarily expressed on the cell surface to allow cell stimulation. Normally when allogeneic CAR T-cell products are created, the T-cell receptor must be eliminated to avoid the graft-versus-host reaction, which is a major safety issue. Importantly, this booster stimulation occurs while preserving the Tscm phenotype.

Poseida Therapeutics expects to launch a clinical trial for its multiple myeloma allogeneic product late this year or early next year. The company will also begin clinical trials later in 2021 on its pan-solid tumor allogeneic program.

Creation of partnerships can help drive development of CAR T-cell therapeutics from concept through clinical trials. Advanced therapies require advanced supply chain and data management, advises Minh Hong, PhD, head of autologous cell therapy, Lonza Pharma & Biotech. Prior biopharmaceutical models of mass production and distributionand the systems that support themare not effective for personalized therapeutics. As manufacturing demand increases for autologous cell therapies, there is an overarching need to both industrialize and simplify the entire supply chain ecosystem.

Hong says the overall project needs to be considered from a more comprehensive perspective: Due to the criticality of the starting material, everything from cell sourcing, patient coordination and scheduling for collection/infusion, transportation logistics, and manufacturing logistics needs to be coordinated, ensuring the highest standards, regulatory compliance, and safety throughout the process.

To meet these needs, Lonza is building a network of partners to develop a fully integrated vein-to-vein solution, that is, a system that includes all touch points involved in patient scheduling and sample collection, through material shipping logistics, manufacturing, and eventually the infusion of the cell therapy back into the patient. The partner network, Hong indicates, will help participants define smart workflows and execute an integration strategy. Hong sums up the networks therapeutic implications as follows: We believe these partnerships will decrease time to clinical program setup.

Lonza has more than a 20-year history of providing clinical and commercial manufacturing. Hong asserts, Our company brings to the table our process development and manufacturing experience along with proprietary solutions including a manufacturing execution system solution, MODA-ESTM, for electronic batch records and manufacturing traceability. In addition, we have announced partnerships with Vineti for a supply chain orchestration system and Cryoport to aid in shipping and logistics.

Lonza is also looking beyond CAR T-cell therapies. We would not limit our solutions and partnerships to autologous cell therapies, Hong declares. We can envision solutions for our in vivo viral vector manufacturing clients as well as our traditional allogeneic cell therapy clients.

Read the original:
CAR T-Cell Optimization Starts in Production, Extends to Therapy - Genetic Engineering & Biotechnology News

Research Reveals Biological Design in the Sensing and Manipulation of Force – Discovery Institute

Photo: A slingshot spider, by Lawrence E. Reeves, via George Institute of Technology/EurekAlert!

A tiny spider has been found that can launch itself at 10 times the speed that would make a test pilot black out. And if that isnt amazing enough, it builds its own catapult out of web material that can tolerate sustained tension for hours and days. The story of the slingshot spider of Peru is told by Georgia Tech. Scientists measured this spiders acceleration at 100 times that of a cheetah, with a force of 130 Gs. How this one-millimeter spider has mastered physics baffles even the engineers who traveled six hours by boat in Peru to watch it in its native habitat.

Another mystery is how the spider patiently holds the web while waiting for food to fly by. Alexander and Bhamla estimated that stretching the web requires at least 200 dynes, atremendous amount of energy for a tiny spider to generate. Holding that for hours could waste a lot of energy.

Generating 200 dynes would produce tremendous forces on the tiny legs of the spider, Bhamla said. If the reward is a mosquito at the end of three hours, is that worth it? We think the spider must be using some kind of trick to lock its muscles like a latch so it doesnt need to consume energy while waiting for hours. [Emphasis added.]

Think of the design requirements for this feat: mastery of materials science, mastery of potential energy to stretch the web and latch it in a cocked position, ability to target fast-moving prey, mastery of ballistics, possessing a body able to withstand exceptional acceleration, and ability to wrap the prey and consume energy from it after a dizzying flight. This is a spider with a PhD in both physics and engineering!

Another example of biological design in the use of force is seen in the flight of the wandering albatross. This bird is fine tuned to wind conditions, say engineers at the University of Liverpool.

With a wingspan of over three meters the largest of any bird alive today the wandering albatross can fly thousands of miles, even around the world, gliding for long periods in search of fish or squid. Birds search for prey in flight and capture it after landing on the sea surface. Due to their long wings, taking off from the sea surface is by far their most energetically demanding activity, requiring four times more energy than gliding flight.

Using data loggers attached to the birds legs, the scientists found that the male albatross, which is 20 percent larger than the female, knows how to take advantage of wind gusts to get launched. On land, the largest wingspan belongs to the California condor. Those birds are known to launch themselves off cliffs or tree branches or run downhill to get airborne. Then they can stay aloft by gliding on thermals.

Scientists can only guess at the mastery of physics of some extinct flyers. Some fossil birds like Pelagonis sandersi had a wingspan almost double that of the wandering albatross 6.4 meters, almost 24 feet! And then there are pterosaurs (flying reptiles); some were as big as giraffes. Some scientists think Quetzalcoatlus northropi, with a wingspan up to 43 feet, could launch itself up into the air in one second from a standing position (see Live Science). If so, the feat required design not only in the muscles to achieve sufficient acceleration but also in the lightweight but sturdy bones that could withstand forces of flight. Indeed, some of the largest dinosaurs may have had specialized bones that were both strong and lightweight to handle the forces of merely standing and walking on the ground, according to New Scientist.

Biology has mastered the use of force all the way down to the nano scale. A paper in PNAS on describes the properties of talin, an adaptor protein that transduces mechanical signals into biochemical cues by recruiting a network of protein ligands in a force-dependent way. This example complements our earlier article about mechanotransduction. Once again, fine tuning of forces and materials is found, but this time at a scale that is orders of magnitude smaller.

These force cues have a complex nature, oscillate in time with different frequency components, and are often embedded in noise. However, most assays to explore the mechanics of force-sensing proteins rely on simple perturbations, such as constant or ramped forces. Here, we use our magnetic tweezers design to subject single talin domains to oscillatory forces and external mechanical noise. We show that talin ignores random external fluctuations but synchronizes its folding dynamics with force oscillations in a frequency-dependent way. We hypothesize that this finely tuned response could underpin talin force-sensing properties.

Talins job as an exquisite force sensor is to grab and hold parts together inside the cell.

Talin is a mechanosensing hub protein in focal adhesions, which cross-links transmembrane integrins with the active F-actin filaments and recruits several binding proteins to control the function and fate of this organelle. For example, vinculin binds to cryptic helices in mechanically unfolded talin domains, subsequently recruiting actin filaments that reinforce the cellular junction. Hence, talin transduces mechanical forces through its folding dynamics.

This enzyme senses motions of neighboring cells or the extracellular matrix. Somehow, talin deconvolves this noisy signals of motion into recognizable oscillations at particular frequencies and knows how to respond. Its spring-like domains unfold so that other molecules can attach, and then it binds them together. It is a truly remarkable reaction that differs from other types of mechanosensing, opening the door for more discoveries in biophysics at the molecular scale:

Although initially formulated in the context of nonlinear physics, stochastic resonance has been demonstrated in a broad range of biological systems, with particular emphasis as a sensory mechanism in mechanoreceptors, like the crayfish hair cells, the cricket cercal system, or the vestibular and auditory system. Interestingly, in all of these examples, signal transduction involves the activation of gated ion channels, which convert mechanical perturbations into electrophysiological signals. However, mechanotransduction also involves biochemical signaling, where force stimuli trigger downstream signaling pathways through a complex network of interacting proteins. In this sense, it remains to be explored whether stochastic resonance could also play a role in mechanotransduction pathways that involve ligand binding to force-bearing proteins instead of gating of mechanosensitive channels.

In the case of talin, the implications for design are clear:

Mechanical signal transduction relies on the robust and finely tuned response of molecular force sensors.Mechanical information is encoded in both the amplitude of the signal and its time-dependent evolution. Hence, both components must be accurately deciphered and interpreted by cellular force sensors.

The only evolution spoken of in the paper is the time-dependent evolution (unfolding) of the vibrations that talin senses: i.e., the behavior of the oscillations from initiation to damping. That ability implies even more design than a simple response to a vibration. It implies that talin can recognize encoded information both in the signal strength and in its behavior in time, and respond accordingly by unfolding the appropriate domain for binding to other protein parts. The three authors from Columbia University describe the actions of this enzyme as a tuning fork of cellular mechanotransduction.

These examples of biological mastery of force are not miracles; they are subject to the laws of physics and obey the laws of physics. But wow, do they know how to take advantage of the laws of physics! From the mightiest dinosaur, to the largest birds, to the tiniest spider, to molecules in the cell, biological designs show how to push the limits of the possible. Such exceptional applications of materials and forces rightly excite our wonder and admiration.

Here is the original post:
Research Reveals Biological Design in the Sensing and Manipulation of Force - Discovery Institute

How Groups of Cells Cooperate to Build Organs and Organisms – The Scientist

Efforts to use regenerative medicinewhich seeks to address ailments as diverse as birth defects, traumatic injury, aging, degenerative disease, and the disorganized growth of cancerwould be greatly aided by solving one fundamental puzzle: How do cellular collectives orchestrate the building of complex, three-dimensional structures?

While genomes predictably encode the proteins present in cells, a simple molecular parts list does not tell us enough about the anatomical layout or regenerative potential of the body that the cells will work to construct. Genomes are not a blueprint for anatomy, and genome editing is fundamentally limited by the fact that its very hard to infer which genes to tweak, and how, to achieve desired complex anatomical outcomes. Similarly, stem cells generate the building blocks of organs, but the ability to organize specific cell types into a working human hand or eye has been and will be beyond the grasp of direct manipulation for a very long time.

But researchers working in the fields of synthetic morphology and regenerative biophysics are beginning to understand the rules governing the plasticity of organ growth and repair. Rather than micromanaging tasks that are too complex to implement directly at the cellular or molecular level, what if we solved the mystery of how groups of cells cooperate to construct specific multicellular bodies during embryogenesis and regeneration? Perhaps then we could figure out how to motivate cell collectives to build whatever anatomical features we want.

New approaches now allow us to target the processes that implement anatomical decision-making without genetic engineering. In January, using such tools, crafted in my lab at Tufts Universitys Allen Discovery Center and by computer scientists in Josh Bongards lab at the University of Vermont, we were able to create novel living machines, artificial bodies with morphologies and behaviors completely different from the default anatomy of the frog species (Xenopus laevis) whose cells we used. These cells rebooted their multicellularity into a new form, without genomic changes. This represents an extremely exciting sandbox in which bioengineers can play, with the aim of decoding the logic of anatomical and behavioral control, as well as understanding the plasticity of cells and the relationship of genomes to anatomies.

Deciphering how an organism puts itself together is truly an interdisciplinary undertaking.

Deciphering how an organism puts itself together is truly an interdisciplinary undertaking. Resolving the whole picture will involve understanding not only the mechanisms by which cells operate, but also elucidating the computations that cells and groups of cells carry out to orchestrate tissue and organ construction on a whole-body scale. The next generation of advances in this area of research will emerge from the flow of ideas between computer scientists and biologists. Unlocking the full potential of regenerative medicine will require biology to take the journey computer science has already taken, from focusing on the hardwarethe proteins and biochemical pathways that carry out cellular operationsto the physiological software that enables networks of cells to acquire, store, and act on information about organ and indeed whole-body geometry.

In the computer world, this transition from rewiring hardware to reprogramming the information flow by changing the inputs gave rise to the information technology revolution. This shift of perspective could transform biology, allowing scientists to achieve the still-futuristic visions of regenerative medicine. An understanding of how independent, competent agents such as cells cooperate and compete toward robust outcomes, despite noise and changing environmental conditions, would also inform engineering. Swarm robotics, Internet of Things, and even the development of general artificial intelligence will all be enriched by the ability to read out and set the anatomical states toward which cell collectives build, because they share a fundamental underlying problem: how to control the emergent outcomes of systems composed of many interacting units or individuals.

Many types of embryos can regenerate entirely if cut in half, and some species are proficient regenerators as adults. Axolotls (Ambystoma mexicanum) regenerate their limbs, eyes, spinal cords, jaws, and portions of the brain throughout life. Planarian flatworms (class Turbellaria), meanwhile, can regrow absolutely any part of their body; when the animal is cut into pieces, each piece knows exactly whats missing and regenerates to be a perfect, tiny worm.

The remarkable thing is not simply that growth begins after wounding and that various cell types are generated, but that these bodies will grow and remodel until a correct anatomy is complete, and then they stop. How does the system identify the correct target morphology, orchestrate individual cell behaviors to get there, and determine when the job is done? How does it communicate this information to control underlying cell activities?

Several years ago, my lab found that Xenopus tadpoles with their facial organs experimentally mixed up into incorrect positions still have largely normal faces once theyve matured, as the organs move and remodel through unnatural paths. Last year, a colleague at Tufts came to a similar conclusion: the Xenopus genome does not encode a hardwired set of instructions for the movements of different organs during metamorphosis from tadpole to frog, but rather encodes molecular hardware that executes a kind of error minimization loop, comparing the current anatomy to the target frog morphology and working to progressively reduce the difference between them. Once a rough spatial specification of the layout is achieved, that triggers the cessation of further remodeling.

The deep puzzle of how competent agents such as cells work together to pursue goals such as building, remodeling, or repairing a complex organ to a predetermined spec is well illustrated by planaria. Despite having a mechanistic understanding of stem cell specification pathways and axial chemical gradients, scientists really dont know what determines the intricate shape and structure of the flatworms head. It is also unknown how planaria perfectly regenerate the same anatomy, even as their genomes have accrued mutations over eons of somatic inheritance. Because some species of planaria reproduce by fission and regeneration, any mutation that doesnt kill the neoblastthe adult stem cell that gives rise to cells that regenerate new tissueis propagated to the next generation. The worms incredibly messy genome shows evidence of this process, and cells in an individual planarian can have different numbers of chromosomes. Still, fragmented planaria regenerate their body shape with nearly 100 percent anatomical fidelity.

Permanent editingof the encoded target morphology without genomic editing reveals a new kind of epigenetics.

So how do cell groups encode the patterns they build, and how do they know to stop once a target anatomy is achieved? What would happen, for example, if neoblasts from a planarian species with a flat head were transplanted into a worm of a species with a round or triangular head that had the head amputated? Which shape would result from this heterogeneous mixture? To date, none of the high-resolution molecular genetic studies of planaria give any prediction for the results of this experiment, because so far they have all focused on the cellular hardware, not on the logic of the softwareimplemented by chemical, mechanical, and electrical signaling among cellsthat controls large-scale outcomes and enables remodeling to stop when a specific morphology has been achieved.

Understanding how cells and tissues make real-time anatomical decisions is central not only to achieving regenerative outcomes too complex for us to manage directly, but also to solving problems such as cancer. While the view of cancer as a genetic disorder still largely drives clinical approaches, recent literature supports a view of cancer as cells simply not being able to receive the physiological signals that maintain the normally tight controls of anatomical homeostasis. Cut off from these patterning cues, individual cells revert to their ancient unicellular lifestyle and treat the rest of the body as external environment, often to ruinous effect. If we understand the mechanisms that scale single-cell homeostatic setpoints into tissue- and organ-level anatomical goal states and the conditions under which the anatomical error reduction control loop breaks down, we may be able to provide stimuli to gain control of rogue cancer cells without either gene therapy or chemotherapy.

During morphogenesis, cells cooperate to reliably build anatomical structures. Many living systems remodel and regenerate tissues or organs despite considerable damagethat is, they progressively reduce deviations from specific target morphologies, and halt growth and remodeling when those morphologies are achieved. Evolution exploits three modalities to achieve such anatomical homeostasis: biochemical gradients, bioelectric circuits, and biophysical forces. These interact to enable the same large-scale form to arise despite significant perturbations.

N.R. FULLER, SAYO-ART, LLC

BIOCHEMICAL GRADIENTS

The best-known modality concerns diffusible intracellular and extracellular signaling molecules. Gene-regulatory circuits and gradients of biochemicals control cell proliferation, differentiation, and migration.

BIOELECTRIC CIRCUITS

The movement of ions across cell membranes, especially via voltage-gated ion channels and gap junctions, can establish bioelectric circuits that control large-scale resting potential patterns within and among groups of cells. These bioelectric patterns implement long-range coordination, feedback, and memory dynamics across cell fields. They underlie modular morphogenetic decision-making about organ shape and spatial layout by regulating the dynamic redistribution of morphogens and the expression of genes.

BIOMECHANICAL FORCES

Cytoskeletal, adhesion, and motor proteins inside and between cells generate physical forces that in turn control cell behavior. These forces result in large-scale strain fields, which enable cell sheets to move and deform as a coherent unit, and thus execute the folds and bends that shape complex organs.

The software of life, which exploits the laws of physics and computation, is enabled by chemical, mechanical, and electrical signaling across cellular networks. While the chemical and mechanical mechanisms of morphogenesis have long been appreciated by molecular and cell biologists, the role of electrical signaling has largely been overlooked. But the same reprogrammability of neural circuits in the brain that supports learning, memory, and behavioral plasticity applies to all cells, not just neurons. Indeed, bacterial colonies can communicate via ionic currents, with recent research revealing brain-like dynamics in which information is propagated across and stored in a kind of proto-body formed by bacterial biofilms. So it should really come as no surprise that bioelectric signaling is a highly tractable component of morphological outcomes in multicellular organisms.

A few years ago, we studied the electrical dynamics that normally set the size and borders of the nascent Xenopus brain, and built a computer model of this process to shed light on how a range of various brain defects arise from disruptions to this bioelectric signaling. Our model suggested that specific modifications with mRNA or small molecules could restore the endogenous bioelectric patterns back to their correct layout. By using our computational platform to select drugs to open existing ion channels in nascent neural tissue or even a remote body tissue, we were able to prevent and even reverse brain defects caused not only by chemical teratogenscompounds that disrupt embryonic developmentbut by mutations in key neurogenesis genes.

Similarly, we used optogenetics to stimulate electrical activity in various somatic cell types totrigger regeneration of an entire tadpole tailan appendage with spinal cord, muscle, and peripheral innervationand to normalize the behavior of cancer cells in tadpoles strongly expressing human oncogenes such as KRAS mutations. We used a similar approach to trigger posterior regions, such as the gut, to build an entire frog eye. In both the eye and tail cases, the information on how exactly to build these complex structures, and where all the cells should go, did not have to be specified by the experimenter; rather, they arose from the cells themselves. Such findings reveal how ion channel mutations result in numerous human developmental channelopathies, and provide a roadmap for how they may be treated by altering the bioelectric map that tells cells what to build.

We also recently found a striking example of such reprogrammable bioelectrical software in control of regeneration in planaria. In 2011, we discovered that an endogenous electric circuit establishes a pattern of depolarization and hyperpolarization in planarian fragments that regulate the orientation of the anterior-posterior axis to be rebuilt. Last year, we discovered that this circuit controls the gene expressionneeded to build a head or tail within six hours of amputation, and by using molecules that make cell membranes permeable to certain ions to depolarize or hyperpolarize cells, we induced fragments of such worms to give rise to a symmetrical two-headed form, despite their wildtype genomes. Even more shockingly, the worms continued to generate two-headed progeny in additional rounds of cutting with no further manipulation. In further experiments, we demonstrated that briefly reducing gap junction-mediated connectivity between adjacent cells in the bioelectric network that guides regeneration led worms to regenerate head and brain shapes appropriate to other worm species whose lineages split more than 100 million years ago.

My group has developed the use of voltage-sensitive dyes to visualize the bioelectric pattern memory that guides gene expression and cell behavior toward morphogenetic outcomes. Meanwhile, my Allen Center colleagues are using synthetic artificial electric tissues made of human cells and computer models of ion channel activity to understand how electrical dynamics across groups of non-neural cells can set up the voltage patterns that control downstream gene expression, distribution of morphogen molecules, and cell behaviors to orchestrate morphogenesis.

The emerging picture in this field is that anatomical software is highly modulara key property that computer scientists exploit as subroutines and that most likely contributes in large part to biological evolvability and evolutionary plasticity. A simple bioelectric state, whether produced endogenously during development or induced by an experimenter, triggers very complex redistributions of morphogens and gene expression cascades that are needed to build various anatomies. The information stored in the bodys bioelectric circuitscan be permanently rewritten once we understand the dynamics of the biophysical circuits that make the critical morphological decisions. This permanent editing of the encoded target morphology without genomic editing reveals a new kind of epigenetics, information that is stored in a medium other than DNA sequences and chromatin.

Recent work from our group and others has demonstrated that anatomical pattern memories can be rewritten by physiological stimuli and maintained indefinitely without genomic editing. For example, the bioelectric circuit that normally determines head number and location in regenerating planaria can be triggered by brief alterations of ion channel or gap junction activity to alter the animals body plan. Due to the circuits pattern memory, the animals remain in this altered state indefinitely without further stimulation, despite their wildtype genomes. In other words, the pattern to which the cells build after damage can be changed, leading to a target morphology distinct from the genetic default.

N.R. FULLER, SAYO-ART, LLC

First, we soaked a planarian in voltage-sensitive fluorescent dye to observe the bioelectrical pattern across the entire tissue. We then cut the animal to see how this pattern changes in each fragment as it begins to regenerate.

We then applied drugs or used RNA interference to target ion channels or gap junctions in individual cells and thus change the pattern of depolarization/hyperpolarization and cellular connectivity across the whole fragment.

As a result of the disruption of the bodys bioelectric circuits, the planarian regrows with two heads instead of one, or none at all.

When we re-cut the two-headed planarian in plain water, long after the initial drug has left the tissue, the new anatomy persists in subsequent rounds of regeneration.

Cells can clearly build structures that are different from their genomic-default anatomical outcomes. But are cells universal constructors? Could they make anything if only we knew how to motivate them to do it?

The most recent advances in the new field at the intersection of developmental biology and computer science are driven by synthetic living machines known as biobots. Built from multiple interacting cell populations, these engineered machines have applications in disease modeling and drug development, and as sensors that detect and respond to biological signals. We recently tested the plasticity of cells by evolving in silico designs with specific movement and behavior capabilities and used this information to sculpt self-organized growth of aggregated Xenopus skin and muscle cells. In a novel environmentin vitro, as opposed to inside a frog embryoswarms of genetically normal cells were able to reimagine their multicellular form. With minimal sculpting post self-assembly, these cells form Xenobots with structures, movements, and other behaviors quite different from what might be expected if one simply sequenced their genome and identified them as wildtype X. laevis.

These living creations are a powerful platform to assess and model the computations that these cell swarms use to determine what to build. Such insights will help us to understand evolvability of body forms, robustness, and the true relationship between genomes and anatomy, greatly potentiating the impact of genome editing tools and making genomics more predictive for large-scale phenotypes. Moreover, testing regimes of biochemical, biomechanical, and bioelectrical stimuli in these biobots will enable the discovery of optimal stimuli for use in regenerative therapies and bioengineered organ construction. Finally, learning to program highly competent individual builders (cells) toward group-level, goal-driven behaviors (complex anatomies) will significantly advance swarm robotics and help avoid catastrophes of unintended consequences during the inevitable deployment of large numbers of artificial agents with complex behaviors.

Understanding how cells and tissues make real-time anatomical decisions is central to achieving regenerative outcomes too complex for us to manage directly.

The emerging field ofsynthetic morphology emphasizes a conceptual point that has been embraced by computer scientists but thus far resisted by biologists: the hardware-software distinction. In the 1940s, to change a computers behavior, the operator had to literally move wires aroundin other words, she had to directly alter the hardware. The information technology revolution resulted from the realization that certain kinds of hardware are reprogrammable: drastic changes in function could be made at the software level, by changing inputs, not the hardware itself.

In molecular biomedicine, we are still focused largely on manipulating the cellular hardwarethe proteins that each cell can exploit. But evolution has ensured that cellular collectives use this versatile machinery to process information flexibly and implement a wide range of large-scale body shape outcomes. This is biologys software: the memory, plasticity, and reprogrammability of morphogenetic control networks.

The coming decades will be an extremely exciting time for multidisciplinary efforts in developmental physiology, robotics, and basal cognition to understand how individual cells merge together into a collective with global goals not belonging to any individual cell. This will drive the creation of new artificial intelligence platforms based not on copying brain architectures, but on the multiscale problem-solving capacities of cells and tissues. Conversely, the insights of cognitive neurobiology and computer science will give us a completely new window on the information processing and decision-making dynamics in cellular collectives that can very effectively be targeted for transformative regenerative therapies of complex organs.

Michael Levinis the director of the Allen Discovery Center at Tufts University and Associate Faculty at Harvard Universitys Wyss Institute. Email him atmichael.levin@tufts.edu. M.L. thanks Allen Center Deputy DirectorJoshua Finkelsteinfor suggestions on the drafts of this story.

Go here to read the rest:
How Groups of Cells Cooperate to Build Organs and Organisms - The Scientist

The Way Cells Move Changes as They Become Cancerous – Technology Networks

In cooperation with colleagues from Germany, Italy and the Netherlands, researchers at Leipzig University have investigated the structure of tumour tissue and the behaviour of tumour cells in detail, gaining important insights that could improve cancer diagnosis and therapy in the future. They found out that during tumour development the way cells move can change from coordinated and collective to individual and chaotic behaviour. They have just published their research findings in the journal Nature Cell Biology.

The paper was supervised by tumour biologist Professor Peter Friedl of Radboud University in Nijmegen, the Netherlands, in cooperation with the research groups headed by Professor Josef A. Ks (Leipzig University), Professor Andreas Deutsch (TU Dresden) and Professor Stefano Zapperi (University of Milan). The scientists studied biological changes that cells usually undergo as cancer develops. The most typical of these is the degradation of the epithelial adhesion molecule E-cadherin. In other words: the cells become less sticky. The researchers showed that this degradation is accompanied by a change in the type of mobility in the tissue. Cells that are more cancerous can move freely past others of their kind, while the epithelial cells are trapped by their neighbours.

It has long been assumed that the reduction in cell stickiness during tumour development increases the mobility of these cancer cells. Our international team was able to confirm this fundamental assumption and show that a dense environment can still hold cancer cells back, said Professor Ks. In his view, it is clear that tumour invasion is strongly influenced by the local environment: cells acting individually can also move in groups if this reduces the resistance of the surrounding tissue. Both types of cell movement led to metastases in the researchers experiments.

Most cancers are carcinomas that develop from epithelial tissue that covers and separates the organs. Its functions include protection and support. Immobile under healthy conditions, cells in this epithelium are a standard example in new research into cell jamming, a field which is currently developing rapidly. This immobility is explained by the fact that the cells are in each others way similar to cars in a traffic jam or individual grains in a pile of sand. And to metastasise, cancer cells need the ability to move through the body. Their phenotype changes during tumour development, moving away from epithelial behaviour.

In experiments on tumour cells taken from patients, the researchers found that cancer cells spread in different ways in different environments: cells with an epithelial phenotype remained in a closed network, in which their movements were coordinated and collective. Less sticky cells in turn became more cancerous, with their cohesion reducing and movements growing more fluid. Individual, less sticky cells separated into the surrounding tissue. This only happens if this tissue is not too dense. This movement is not coordinated, in step, as it would be in cells with an epithelial phenotype, but random and not coordinated with adjacent cells, said doctoral researcher Jrgen Lippoldt from Leipzig University. In order to turn this understanding into an advantage for cancer patients, further research is needed to find out which migration method can lead to metastases under which circumstances.

Reference:Ilina O, Gritsenko PG, Syga S. et al. Cellcell adhesion and 3D matrix confinement determine jamming transitions in breast cancer invasion. Nat Cell Biol. 2020. doi:https://doi.org/10.1038/s41556-020-0552-6

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original:
The Way Cells Move Changes as They Become Cancerous - Technology Networks

New EU research project seeks to kickstart the development of "Organoid Cell Atlas" – News-Medical.net

Reviewed by Emily Henderson, B.Sc.Aug 31 2020

HCA|Organoid is a new EU research project that combines single-cell profiling and organoid technology to validate organoids as faithful models of human biology. The project seeks to kickstart the development of an open access "Organoid Cell Atlas". By creating well-characterized in vitro models of human organs, this resource will enable future discovery-driven and translational research on rare genetic diseases, complex multifactorial diseases, and on cancer. Toward this goal, Europe's leading organoid researchers as well as experts in single-cell sequencing, single-cell imaging, and computational data integration have teamed up.

The HCA|Organoid project is one of six pilot actions funded by the EU Horizon 2020 Framework Program that will constitute European contributions to the "Human Cell Atlas" - an ambitious global initiative striving to advance biomedical research and therapy using single-cell technologies. The HCA|Organoid consortium comprises eight partners and will receive EUR 5 million in EU funding.

Single-cell technologies provide a fundamentally new perspective for understanding biology, with profound potential to enable therapeutic advances and to put Europe at the forefront of personalized medicine and regenerative biology. In order to streamline research and accelerate scientific progress in this area, the Human Cell Atlas (HCA) initiative provides worldwide coordination toward the goal of establishing comprehensive reference maps of all cell types in the human body.

Within the global context provided by the HCA, the new European research project HCA?Organoid has set out to establish an "Organoid Cell Atlas". This initiative will firmly establish single-cell analysis of human organoids within the HCA and thereby advance biomedical research. This vision is outlined in a strategy paper that is publicly available as a preprint (DOI: 10.5281/zenodo.4001718). In a nutshell, researchers will use single-cell data as a "Rosetta stone", helping to translate between results obtained from tissue samples of patients and analyses of the experimentally more flexible organoids grown in vitro (which constitute "patient avatars" in the laboratory). For example, researchers may identify a novel disease-associated cell type in primary patient samples, create equivalent cells in human organoids, and then investigate potential therapeutic strategies in vitro.

Toward realizing this vision, HCA|Organoid project will initially focus on establishing single-cell transcriptomes, epigenomes, and time-series imaging of human organoids and matched primary tissue from healthy donors. The project will derive and comprehensively characterize human brain and colon organoids from 100 individuals each, in order to capture population variation and to establish a comprehensive reference for disease-centric research. The single-cell maps will be integrated into a public Organoid Cell Atlas Portal, which will provide user-friendly access to single-cell data of organoids in connection to human primary samples. This scientific resource will support several proof-of-concept studies, for example focusing on disease modeling for genetic epilepsy in brain organoids, on organoid cancer models, and on the characterization of disease-linked genetic variants in colon organoids.

The HCA-Organoid project brings together a consortium of eight partner institutions including experts in organoid technology, single-cell profiling, advanced imaging, and bioinformatics from Austria, Germany, the Netherlands and Switzerland. In addition to its initial focus on single-cell profiling of brain and colon organoids, the project seeks to initiate an open, collaborative network of researchers and initiatives aimed at the single-cell characterization of a diverse set of human organoids.

We are excited to combine single-cell profiling with organoid technology, and to contribute a focus on human organoids to the Human Cell Atlas. These are complementary technologies that together will bring us an important step closer to the rational development of future therapies for a wide range of diseases."

Christoph Bock, project coordinator and principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences

Source:

Journal reference:

Bock, C., et al. (2020) The Organoid Cell Atlas: A Rosetta Stone for Biomedical Discovery and Regenerative Therapy. Zenodo. doi.org/10.5281/zenodo.4001718.

Read more from the original source:
New EU research project seeks to kickstart the development of "Organoid Cell Atlas" - News-Medical.net

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor in a Blinded Randomized Phase 2 Trial for Immune Mediated…

Trial to evaluate the efficacy of Quellor to blunt the cytokine storm and decrease the catastrophic complications of COVID-19 infection.

LA JOLLA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced today that the U.S. Food and Drug Administration (FDA) has accepted the companys Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Quellor, a selective soluble tumor necrosis factor (sTNF) inhibitor, for the treatment of immune mediated complications in COVID-19 patients.

There is compelling evidence thatTNFplays an outsized role in the pathology caused by the cytokine storm, stated RJ Tesi, MD, Chief Executive Officer of INmune Bio. We can now move to the clinic to determine if neutralizing soluble TNF, the master cytokine of the cytokine storm, will blunt the effects of this dysregulated innate immune response to the SARS-CoV-2 virus without immunosuppressing the patient.

The blinded randomized Phase 2 clinical trial (NCT04370236) will enroll 366 COVID-19 patients in two equal sized cohorts: standard of care (SOC), which may include remdesivir or SOC plus Quellor given as a 1mg/kg subcutaneous injection on admission to the hospital. A second dose of Quellor may be given a week later if the patient remains hospitalized. The primary study endpoint is the need for mechanical ventilation during the 28 days following admission to the hospital, including CPAP, BiPAP or intubation. Secondary endpoints include transfer to the ICU, new onset neurologic, cardiovascular or thromboembolic disease, development of renal failure or death. The first 100 patients randomized into the study will provide proof-of-concept and inform a go/no go decision by the Data Safety Monitoring Board (DSMB). If the DSMB recommends that the trial continue, the remaining 266 patients will be enrolled.

About Quellor

Quellor is a next-generation inhibitor of tumor necrosis factor (TNF) that is different from currently existing non-selective TNF inhibitors. Quellor neutralizes soluble TNF (sTNF) using a novel dominant-negative biology that importantly does not affect trans-membrane TNF (tmTNF) or TNF receptors. Currently approved TNF inhibitors block both sTNF and tmTNF. Quellor could have beneficial effects in patients with immune mediated complications from COVID-19 by decreasing inflammation and inflammatory immune complications such as endothelial cell activation, a potentially important cause of COVID-19-related coagulopathy which is increasingly blamed for end-organ dysfunction in lungs, kidneys, heart and brain. By targeting only sTNF, Quellor does not cause immunosuppression that is typical of most anti-cytokine therapies including currently approved anti-TNF and anti-IL-6 therapies. This may be an advantage when treating patients with a life-threatening viral infection.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers (XPro595), and NASH (LIVNate). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patients NK cells to eliminate minimal residual disease in patients with cancer.INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visitwww.inmunebio.com.

Informationabout Forward-Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03, Quellor, XPro1595, LIVNate, and INKmune are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:David Moss, CFO (858) 964-3720DMoss@INmuneBio.com

Investor Contact:Chuck PadalaLifeSci Advisors(646) 627-8390chuck@lifesciadvisors.com

Media Contact:Meredith Sosulski, Ph.D. LifeSci Communications(929) 469-3851msosulski@lifescicomms.com

Follow this link:
INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor in a Blinded Randomized Phase 2 Trial for Immune Mediated...